Odonate Therapeutics, Inc.
Other OTCTotal Valuation
Odonate Therapeutics, Inc. carries a market capitalization of 8.05B, placing it among publicly traded companies globally. Its enterprise value stands at -12.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.05B |
| Enterprise Value | -12.28M |
Share Statistics
Odonate Therapeutics, Inc. currently has 481.00 shares outstanding.
| Shares Outstanding | 481.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.12 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | -0.69 |
| P/OCF Ratio | -0.69 |
Financial Position
Odonate Therapeutics, Inc. maintains a current ratio of 4.75, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.75 |
| Quick Ratio | 4.35 |
| Debt / Equity | 7.87 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -55.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Odonate Therapeutics, Inc.'s stock has declined approximately -83.32955% over the past 52 weeks. The 50-day moving average sits at 150,188.00, while the 200-day moving average is 139,977.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -83.32955% |
| 50-Day Moving Average | 150,188.00 |
| 200-Day Moving Average | 139,977.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -77.95M, while operating income came in at -78.43M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -78.43M |
| Pretax Income | -68.31M |
| Net Income | -68.31M |
| EBITDA | -77.95M |
| EBIT | -78.43M |
| Earnings Per Share (EPS) | -142,027.03 |
Balance Sheet
Odonate Therapeutics, Inc. holds 68.89M in cash and equivalents against 4.67M in total debt, resulting in a net debt position of -68.89M. Total book value stands at -434.46M, with working capital of 59.32M providing operational flexibility.
| Cash & Cash Equivalents | 68.89M |
| Total Debt | 4.67M |
| Net Debt | -68.89M |
| Equity (Book Value) | -434.46M |
| Book Value Per Share | -903,234.93 |
| Working Capital | 59.32M |
Cash Flow
Odonate Therapeutics, Inc. produced -75.72M in operating cash flow over the past twelve months. After subtracting -26,000.00 in capital expenditures, free cash flow totaled -75.75M - equivalent to -157,486.49 per share.
| Operating Cash Flow | -75.72M |
| Capital Expenditures | -26,000.00 |
| Free Cash Flow | -75.75M |
| FCF Per Share | -157,486.49 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 24.54 |
| FCF Yield | -145.72 |
Stock Splits
Odonate Therapeutics, Inc.'s most recent stock split took place on January 15, 2025 with a 8:1 split ratio.
| Last Split Date | 1/15/2025 |
| Split Ratio | 8:1 |
Scores
Odonate Therapeutics, Inc. posts an Altman Z-Score of -8.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -8.50 |